#USA #New Orleans #Bio-Techne #Kytopen #TcBuster

Kytopen and Bio-Techne Collaborate to Revolutionize Cell Therapy Manufacturing

In an exciting development for the life sciences sector, Kytopen Corp. and Bio-Techne Corporation have announced a strategic partnership focused on an integrated cellular engineering workflow. This collaboration is designed to significantly expedite the manufacturing processes of advanced cell therapies, vital for enhancing patient treatment options.

With the introduction of the TcBuster™ system, Kytopen aims to streamline gene delivery mechanisms. This innovative technology allows for the integration of large gene payloads into cells with exceptional editing efficiency using a single vector. Meanwhile, Bio-Techne's Flowfect® technology complements this by providing a gentle but effective method for processing billions of cells in just a matter of minutes.

The Power of Combined Technologies

The collaboration between Kytopen and Bio-Techne utilizes the strengths of both companies to tackle the challenges faced in cell therapy production. The TcBuster™ system, a non-viral platform, replaces traditional lentivirus methods, which have several limitations in terms of safety and efficiency. With TcBuster, the hyperactive transposase mechanism enables the concurrent delivery of multiple genes while maintaining a reliable safety profile and high editing accuracy.

When paired with Bio-Techne's Flowfect® continuous flow technology, the potential is vast. This technology integrates mechanical, electrical, and chemical approaches to optimize transfection efficiencies, ensure cell viability, and enhance overall cell yield. Continuous flow processing allows for hundreds of billions of high-quality engineered cells to be produced swiftly, facilitating fast-track pathways for cell therapies from the lab to clinical settings.

Implications for Clinical Development

Both companies have expressed their enthusiasm about merging their technologies. Kevin Gutshall, Chief Commercial Officer at Kytopen, emphasized the importance of this partnership in bringing more effective cell therapies to market. He noted that their non-viral gene-editing platform is particularly advantageous for immune cells, especially those that do not divide or are sensitive to cell death.

As Kytopen and Bio-Techne prepare to present their findings, the impact of their collaboration is already making waves in the industry. At the upcoming International Society for Cell and Gene Therapy (ISCT) Annual Meeting in New Orleans, data from their collaboration will be showcased on posters and through oral presentations. This engagement highlights the importance of collaborative efforts in pushing the boundaries of what's possible in cell therapy.

Presentations will outline the advantages of their integrated workflow and how it leads to more reliable and scalable solutions for engineered cell manufacturing. Specifically, their poster presentation entitled "Continuous Flow Transfection with Flowfect® Technology as an Efficient, Non-Viral Technology for Scalable CRISPR-Mediated Engineering of Primary T Cells" aims to draw significant attention from global experts in cell therapy.

Looking Ahead

The partnership between Kytopen and Bio-Techne is set against a backdrop of rapid innovations in biotechnology. As more clinical trials begin to explore advanced cellular therapies, the need for efficient manufacturing processes becomes critical. This collaboration stands to revolutionize how engineered cells are produced, with the potential to significantly reduce the time and complexity involved in bringing new therapies to patients.

Overall, Kytopen's bold technological advancements complemented by Bio-Techne's established presence in life science tools are paving the way for the next era of cell therapy manufacturing. By leveraging each other's unique capabilities, they are set to transform patient outcomes and address some of the most pressing challenges in the field of regenerative medicine. As these technologies mature and gain traction in the industry, the horizon looks promising for groundbreaking therapies that can change lives, embodying the future of cell-based medicine.

These advancements will not only enhance productivity but also ensure that more patients can benefit from these innovative treatments sooner rather than later. With Kytopen and Bio-Techne leading the charge, the landscape of cell therapy is undoubtedly on the brink of transformative change.